JOHNSON & JOHNSON (JNJ)
As-reported financials and recent SEC filings for JOHNSON & JOHNSON, latest fiscal period FY2025. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About JOHNSON & JOHNSON
Johnson & Johnson is a global healthcare company that operates through two main segments: Innovative Medicine and MedTech. The Innovative Medicine segment develops and sells prescription medicines for various therapeutic areas including oncology, immunology, neuroscience, infectious diseases, and cardiovascular conditions. The MedTech segment designs and manufactures medical devices and products used in cardiovascular care, orthopaedics, surgery, and vision, serving healthcare professionals, hospitals, and eye care providers worldwide.
Snapshot
Fundamentals are from SEC filings. P/E and market cap are derived from recent market prices, refreshed on a rolling basis (typically within the past week).
What changed at Johnson & Johnson
- Revenue grew 6.0% to $94.2B in FY2025, in line with the 4.3% the year before.
- Most recent quarter Q2 FY2026: revenue $25.3B, up 6.6% from Q2 FY2025.
- Free cash flow was $19.7B in FY2025, 20.9% of revenue.
- Net income rose 90.6% to $26.8B in FY2025.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Johnson & Johnson’s fundamentals sit among the 199 pharmaceutical companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
Johnson & Johnson’s return on equity of 32.9% ranks in the 90th percentile of the 168 pharmaceutical companies reporting it.
No open-market insider buys in the last 90 days; 2 insider sales totaling $8.2M. For context, about 16% of companies in the universe saw any open-market insider buying in the same window. Browse insider activity →
Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Institutional ownership
Held by 6 of the superinvestors we track (plus 5 quant / multi-strat books), based on each investor’s most recent 13F (latest Q1 2026).
| Investor | As of | Position value | Shares | Change |
|---|---|---|---|---|
| AQR Capital Managementquant | Q1 2026 | $864.3M | 3.5M | Reduced |
| Citadel Advisorsquant | Q1 2026 | $472.0M | 1.9M | Added |
| Yacktman Asset Management | Q1 2026 | $305.4M | 1.2M | Reduced |
| D. E. Shawquant | Q1 2026 | $186.9M | 764.5K | Reduced |
| Bridgewater Associates | Q1 2026 | $170.3M | 696.9K | Reduced |
| Markel Group | Q1 2026 | $149.3M | 610.8K | Held |
| Millennium Managementquant | Q1 2026 | $140.7M | 575.7K | Reduced |
| Gotham Asset Management | Q1 2026 | $55.6M | 227.4K | Reduced |
| Two Sigma Investmentsquant | Q1 2026 | $13.0M | 53.3K | Added |
| Soros Fund Management | Q1 2026 | $8.5M | 34.8K | New |
| Dodge & Cox | Q1 2026 | $5.1M | 20.9K | Held |
No longer held by: Point72 Asset Management (as of Q1 2026)
From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.
Recent insider activity
Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.
| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
2026-07-20 filed 2026-07-21 | Broadhurst VanessaEVP, Global Corp Affairs | Sell | 23.1K | $251.27 | $5.8M |
2026-06-11 filed 2026-06-12 | Wengel Kathryn EEVP, Chief TO and Risk Officer | Sell | 10.0K | $241.15 | $2.4M |
Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-07-15 | 27.4M | +3.2% | 3.67 |
| 2026-06-30 | 26.6M | -0.4% | 2.48 |
| 2026-06-15 | 26.7M | +14.0% | 3.61 |
| 2026-05-29 | 23.4M | +1.6% | 2.95 |
| 2026-05-15 | 23.0M | +3.1% | 3.06 |
| 2026-04-30 | 22.3M | +13.6% | 2.74 |
| 2026-04-15 | 19.7M | -11.7% | 2.78 |
| 2026-03-31 | 22.3M | -4.5% | 2.76 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B |
| Operating income | — | — | — | — | — |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B |
| Diluted EPS | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full methodology.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash and equivalents | $19.71B | $24.11B | $21.86B | $12.89B | $14.49B |
| Current assets | $55.62B | $55.89B | $53.49B | $55.29B | $60.98B |
| Total assets | $199.21B | $180.10B | $167.56B | $187.38B | $182.02B |
| Current liabilities | $54.13B | $50.32B | $46.28B | $55.80B | $45.23B |
| Long-term debt | $39.44B | $30.65B | $25.88B | $26.89B | $29.98B |
| Total liabilities | $117.67B | $108.61B | $98.78B | $110.57B | $108.00B |
| Total equity | $81.54B | $71.49B | $68.77B | $76.80B | $74.02B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full methodology.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating cash flow | $24.53B | $24.27B | $22.79B | $21.19B | $23.41B |
| Capital expenditure | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B |
| Free cash flow | $19.70B | $19.84B | $18.25B | $17.18B | $19.76B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full methodology.
Quarterly trend (as reported)
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q2 FY2026 | $25.31B | 6.6% | $5.53B | $2.27 |
| Q1 FY2026 | $24.06B | 9.9% | $5.24B | $2.14 |
| Q4 FY2025 | $24.56B | 9.1% | $5.12B | $2.09 |
| Q3 FY2025 | $23.99B | 6.8% | $5.15B | $2.12 |
| Q2 FY2025 | $23.74B | 5.8% | $5.54B | $2.29 |
| Q1 FY2025 | $21.89B | 2.4% | $11.00B | $4.54 |
| Q4 FY2024 | $22.52B | 5.3% | $3.43B | $1.41 |
| Q3 FY2024 | $22.47B | 5.2% | $2.69B | $1.11 |
Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.
Company facts
Recent SEC filings
Largest pharmaceutical peers
JNJ head to head
Monitor JNJ
Get an alert when Johnson & Johnson files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor JNJ freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.